Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Trial Profile

Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant
  • Indications Haemophilus infections; Hepatitis A; Hepatitis B; Otitis media; Pneumonia; Streptococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Mar 2018 Results assessing vaccine preventable disease incidence using patient data from NCT00861380 and NCT00839254 trials published in the Vaccine
    • 30 Apr 2013 Results presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
    • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2008-006551-51).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top